It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
It’s important to lay strong foundations for successful drug discovery at this first stage of the process. Our integrated target identification and validation platform combines AI with expert insights, and rigorous lab validation to guide targets through robust evaluation, ready for hit discovery.
Validated, high-quality hits, delivered through integrated technologies and expert collaboration, give you a confident starting point for faster drug discovery.
Turning promising leads into clinical candidates with speed, precision, and the scientific expertise to generate high-quality data and deliver real patient impact.
Delivering integrated, modality-agnostic drug discovery to tackle complex biology, accelerate development, and advance innovative therapies with confidence.
Advancing next-generation ADCs through payload-focused design, integrated expertise, and collaborative innovation to deliver safer, more selective therapies.
Driving biologics innovation through integrated design, structural biology, and multidisciplinary expertise to accelerate next-generation therapies from concept to clinic.
Combining deep therapeutic expertise with translational insight to design strategies, reduce risk, and accelerate discovery programs toward clinical success.
Accelerating oncology drug discovery through integrated expertise, innovative modalities, and translational insight to deliver candidates with real clinical impact.
Driving immunology and inflammation drug discovery through tailored assays, translational models, and integrated expertise for faster clinical success.
Advancing CNS drug discovery through integrated models, translational biomarkers, and multidisciplinary expertise to overcome complexity and accelerate therapeutic innovation.
Designing and advancing differentiated small-molecule therapies for obesity and diabetes through integrated expertise, mechanistic insight, and translational strategies.
Inobrodib, an exciting, first-in-class oral anti-cancer drug in clinical development by CellCentric, was collaboratively designed, synthesised and supported on its pre-clinical journey by an integrated project team at Sygnature Discovery. Inobrodib is now showing promising results in Phase I and II trials for multiple myeloma and other cancer types.
High performance cellular reagents designed with your research goals in mind.
Drug discovery relies on cell-based assay systems to understand target function and how modulation affects cellular processes. High quality stable monoclonal cell lines deliver consistent expression and assay reproducibility, supporting robust high throughput screening and downstream medicinal chemistry cascades with confidence in the data.
Using the latest technologies and thoughtful design, our scientists evaluate hundreds of individual clones at each stage and progress only the best performers. This end-to-end approach delivers rapid and cost-effective stable cell lines and assay systems, reducing workload for your team while keeping you involved in key decisions.
Our Customizable Cell Line Generation Process
Our streamlined process creates reliable and consistent stable cell reagents with robust expression of your target.
1. Precision Construct Design
Custom expression constructs for optimal target expression and functionality.
2. Optimized Transfection
High efficiency transduction of challenging cell types and validation of target functionality.
3. Antibiotic Selection
Optimal selection conditions for single and multiple gene expression using your specific cell type of choice.
4. Clonal Isolation
Isolation of individual cell clones using limiting dilution and expansion under antibiotic selection.
5. Functional Profiling
Thorough screening and assessment of functional activity of isolated clones to select the best candidates.
6. Quality Check
Comprehensive quality control criteria to confirm pharmacology, expression stability and reliability.
7. Stock Generation
Expansion and preparation of cell stocks for future applications.
We deliver fully validated stable monoclonal cell lines tailored to your biology and assay format, including:
Physiologically relevant target expression with robust assay windows
Surface localization and trafficking optimization for challenging membrane proteins
Multi gene and complex pathway systems, including co-expression and ratio control
Inducible expression for toxic targe roe when on and off comparisons are needed
Tagged or antibody independent detection when reagents are limited
HTS ready performance supported by deep clonal screening
Target Classes & Advanced Systems
Our team generates and validates recombinant cell lines across many demanding target families, including ion channels, GPCRs, transporters and cytosolic proteins. We also build advanced cellular tools such as reporter systems, protein-protein interaction models, internalization/trafficking platforms, and real-time signalling biosensors to meet modern discovery needs.
Why Choose Sygnature Discovery for Cell Line Generation Support?
For more than two decades, we have generated high-quality recombinant cell lines across challenging targets, analyzing hundreds of clones per project to deliver the strongest reagents. We bring deep knowledge of expression systems, host cell types, and troubleshooting strategies that de-risk complex programs. We collaborate with your team, while allowing you to focus on the rest of the discovery research.
Delivering Custom Cell-Based Tools for Drug Discovery
Ebook
Drug Discovery research heavily relies on cell-based assay systems to investigate cellular functions and processes, and to help understand the effect of modulating specific molecular targets. Challenges associated with the use of primary cultures, such as availability, scalability, and cost, make recombinant cellular systems indispensable for drug discovery. High quality… Read More
Explore cutting-edge insights into small molecule innovations driving obesity and weight…
Posters
Related Solutions
We bring together a dynamic blend of new talent and experienced pharmaceutical industry experts from a round the world, delivering excellence across every stage of discovery.
Integrated hit identification using HTS, fragment screening, and advanced automation delivering high-quality starting points for successful drug discovery.
Comprehensive ion channel assays and bespoke cell lines deliver high-fidelity screening and safety insights, accelerating hit-to-lead and optimization.
Advanced transporter assays and electrophysiology deliver robust, high-throughput data for hit identification, validation, and lead optimization in drug discovery.
